Skip to main content
SP5007,652.30-0.29%DOW53,450.99+0.33%NASDAQ25,975.12-0.78%BTC$78,470.00+1.30%ETH$2,492.52+1.37%GOLD$4,730.30+1.06%OIL$85.75-1.50%
Smart Investors Daily
Sign InSign Up Free
PP

NASDAQ · PPCB

Propanc Biopharma, Inc. Common Stock

Healthcare · Biotechnology

$1.08

Up+$0.06 (+5.09%)

Updated Aug 24, 2026, 2:02 PM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
9.77M
P/E ratio
-0.15
Dividend yield
0.00%
52-week range
$0.09 – $6.79
Volume
25.22K
Avg. volume
330.85K

Price performance

PPCB price history

1M range · 20 trading sessions · Daily adjusted prices

PPCB closed at $1.08 after 20 trading sessions, down 18.18% for the selected period.

Last close
$1.08
Period change
-18.18%
Period low
$0.99
Period high
$1.36
Daily close
View OHLC price history
PPCB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 21, 2026$1.12$1.12$1.05$1.0825.22K
Aug 20, 2026$1.13$1.18$1.10$1.1020.83K
Aug 19, 2026$1.185$1.185$1.10$1.1436.89K
Aug 18, 2026$1.12$1.1938$1.10$1.1633.09K
Aug 17, 2026$1.25$1.27$1.15$1.1546.6K
Aug 14, 2026$1.21$1.29$1.20$1.2239.54K
Aug 13, 2026$1.24$1.26$1.20$1.2234.46K
Aug 12, 2026$1.23$1.26$1.17$1.2139.06K
Aug 11, 2026$1.18$1.24$1.16$1.1744.17K
Aug 10, 2026$1.20$1.2378$1.065$1.1583.63K
Aug 7, 2026$1.22$1.26$1.18$1.20193.45K
Aug 6, 2026$1.25$1.60$1.10$1.361.23M
Aug 5, 2026$1.06$1.32$1.05$1.18595K
Aug 4, 2026$1.10$1.10$0.9776$1.0247.65K
Aug 3, 2026$1.02$1.07$1.00$1.0575.6K
Jul 31, 2026$1.07$1.08$0.95$1.0139.35K
Jul 30, 2026$1.00$1.0843$0.97$1.0447.91K
Jul 29, 2026$1.19$1.24$0.95$0.99187.71K
Jul 28, 2026$1.29$1.30$1.17$1.2178.3K
Jul 27, 2026$1.33$1.3599$1.20$1.3250.35K

Latest PPCB news

The latest Smart Investors Daily articles mentioning PPCB.

Stock researchCompany · Overview

PPCB research

Overview

Company profile and research snapshot.

Company profile

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 12, 2026

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Contrasting Science with Revolution Medicines and ErascaMELBOURNE, Australia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today provided a scientific comparison of its lead candidate PRP with the RAS-targeted approaches of Revolution Medicines, Inc. and Erasca, Inc. The Company articulates why PRP’s unique m

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By